Key facts
- Notable investors include Oriental Fortune Capital, Shanghai Healthcare Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Bundxcell
- ·The full record, as it builds
Funding rounds
No funding rounds for Bundxcell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bundxcell
Developer of a biopharmaceutical pipeline designed to create first-in-class innovative drugs addressing major unmet clinical needs in degenerative and immune diseases. The company offers dual technology platforms integrating induced pluripotent stem cells and tissue-specific small molecules, enabling global healthcare markets to access breakthrough treatments that advance the frontiers of cell therapy and regenerative medicine.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Bundxcell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bundxcell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bundxcell in its N-PORT filings yet. We sweep new filings monthly.